Photocure ASA, known as The Bladder Cancer Company, highlighted significant advancements in bladder cancer diagnostics and management during the American Urological Association Annual Congress 2025 held in Las Vegas. The company presented four abstracts focusing on the efficacy of Blue Light Cystoscopy (BLC®), emphasizing its role in enhancing risk stratification and aiding informed clinical decisions.
Innovative Research from Photocure’s Blue Light Cystoscopy Registry
At the congress, three key studies emerged from Photocure’s extensive U.S. Blue Light Cystoscopy with Cysview Registry. This registry, established in 2014, consolidates real-world data from multiple centers, aiming to enroll 4,400 bladder cancer patients. One study by Duke University’s Alireza Ghoreifi revealed that BLC detected an additional 7% of malignant lesions not identified by White Light Cystoscopy (WLC), leading to a 9.3% increase in tumor grading and staging accuracy. These findings suggest that BLC can significantly influence treatment pathways, including the administration of intravesical therapy and decisions regarding radical cystectomy.
Enhancing Predictive Models for Bladder Cancer Outcomes
Harvard University’s Boris Gershman presented two studies addressing the predictive capabilities of BLC in non-muscle invasive bladder cancer (NMIBC). The first study developed models to forecast recurrence and progression using data from 1,109 patients, identifying key risk factors such as tumor number and recurrence status. The second study evaluated the performance of established EORTC and CUETO models against the new BLC-based models, demonstrating that traditional models underperformed in the context of BLC-enhanced procedures. These insights underscore the necessity for updated predictive tools tailored to contemporary treatment methods.
• BLC identifies malignant lesions missed by traditional methods
• Enhanced staging influences critical treatment decisions
• Existing predictive models are inadequate for BLC data
• Personalized management strategies can be developed using BLC insights
Furthermore, the CUT-less trial presented by Francesco del Guidici from Sapienza University explores the potential to eliminate secondary resections in selected NMIBC patients by integrating multiparametric MRI and PDD-guided TURBT. This approach aims to reduce the procedural burden on patients without compromising recurrence rates, highlighting Photocure’s commitment to patient-centered care.
Photocure’s interactive booth at the AUA 2025 also provided attendees with hands-on demonstrations of the BLC with Cysview procedure, showcasing the Saphira HD equipment. These practical sessions, along with expert-led technical talks, reinforced the company’s dedication to advancing bladder cancer diagnostics and treatment technologies.
As bladder cancer remains one of the most common and costly cancers globally, Photocure’s innovative solutions offer significant improvements in patient outcomes and healthcare efficiency. By leveraging real-world data and developing modern predictive models, Photocure is setting new standards in the management of non-muscle invasive bladder cancer.
Ultimately, Photocure’s presentations at AUA 2025 demonstrate the transformative potential of Blue Light Cystoscopy in enhancing diagnostic accuracy and personalized treatment strategies for bladder cancer patients. The company’s ongoing research and technological advancements promise to deliver more effective and tailored care options, addressing both clinical and economic challenges associated with bladder cancer management.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
